FDA Panel Votes Against Investigational ALS Treatment Introduction In a blow to patients and researchers alike, nearly all members of the FDA‘s Cellular, Tissue, and Gene Therapy Advisory Committee voted against the data presented for an investigational amyotrophic lateral sclerosis (ALS) treatment. This decision, which came in a 17-1 vote, stated that the data presented […]
FDA Advisers Vote Against Experimental ALS Treatment Pushed By Patients Background In a recent meeting, federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis (ALS). This decision comes after years of effort by patients seeking access to the unproven therapy. The treatment in question, called […]
